Stimulation of PTHrP release initiates a vicious circle of hypercalcemia maintained by CaSR expression in Leydig cell tumors, which suggests CaSR as a potential therapeutic target for CaSR antagonists. This evidence concerns the gene PTHLH and hypercalcemia disease.